← DOOMRADAR

markets · Published brief

Novartis shares fall after pelacarsen trial failure

Novartis shares fell 1.9% after failure of the pelacarsen trial erased CHF4.9 billion in market value. The setback affects development of the company's cardiovascular treatment candidate.

By DoomRadar · Published on DoomRadar .

Why it matters

The result materially affects Novartis's valuation and the prospects for a major cardiovascular drug program.

Related source links

These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.

  1. Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion ↗finance.yahoo.com · Recorded source date: Sep 7, 2026, 6:02 PM UTC

AI-assisted, source-based analysis. Methodology · Report a correction

Connected by topic or specific details. Dates below are publication dates; the articles may describe separate events.

MORE RECENT READING

Amgen shares fall after trial failure clouds cholesterol-drug prospects

Amgen shares fell 10% after a Novartis trial failure raised concerns about the cholesterol-drug class; Novartis shares reportedly fell 14%. The development affected major pharmaceutical companies and investor expectations.

Related details in the reporting

MORE RECENT READING

Novartis trial setback sends shares lower

Novartis shares fell after a setback in the company's latest clinical trial. The supplied information does not specify the drug, trial outcome or scale of the decline.

Related details in the reporting

More in Markets & economy → · Browse the event archive →